E2496 / NCI-C / SWOG / CALG-B: ABVD vs Stanford V in Locally Extensive and Advanced Stage Hodgkin Lymphoma (HL) Gordon LI, et al. ECOG 2496, J Clin Oncol.

Slides:

Advertisements

Similar presentations

Gopal AK et al. Proc ASH 2013;Abstract 4382.

Advertisements

Vervolg CASUS. september inmiddels 6 kuren R-CVP ondergaan -restadiering: PR EN NU?

LaCasce A et al. Proc ASH 2014;Abstract 293.

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation 1 Phase III Randomized, Open-Label, Multicenter Trial (BRIM3) Comparing BRAF Inhibitor.

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

Eastern cooperative oncology group E1496: ECOG and CALGB Cyclophosphamide/Fludarabine (CF) with or without Maintenance Rituximab (MR) in Advanced Indolent.

HELIOS – Klinikum Erfurt

LUNG CANCER: ASCO 2006 TOPICS Adjuvant therapy Clinical studies Meta-analysis ChemoXRT for stage III disease Advances in stage IV NSCLC New agents Predictive.

1 Non–Small-Cell Lung Cancer Diagnosis and Staging EvaluationPurpose Physical examinationIdentify signs Chest x-rayDetermine position, size, number of.

Howard M. Sandler, MD University of Michigan Medical School

Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma Younes A et al. Proc.

Anas Younes, M.D. Director, Clinical & Translational Research

What to do in stage III non small-cell lung cancer? Miklos Pless 28. November 2013.

Involved Field Radiotherapy versus No Further Treatment in Patients with Clinical Stages IA/IIA Hodgkin Lymphoma and a “Negative” PET Scan After 3 Cycles.

Sequential Dose-Dense R-CHOP Followed by ICE Consolidation (MSKCC Protocol ) without Radiotherapy for Patients with Primary Mediastinal Large B Cell.

Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.

Gemcitabine + Cisplatin +/- Bevacizumab as 1st-line Treatment of Advanced NSCLC: AVAiL Study Manegold PASCO 25:#7514, 2007/Ann.

Rituximab maintenance for the treatment of indolent NHL Dr Christian Buske.

Optimizing Timing of Transplant in Hodgkin Lymphoma Ginna G. Laport, MD Associate Professor of Medicine Division of Blood & Marrow Transplantation Stanford.

A Randomized Phase II Study Comparing Consolidation with a Single Dose of 90 Y Ibritumomab Tiuxetan (Zevalin ® ) (Z) vs Maintenance with Rituximab (R)

Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.

Dose-Adjusted EPOCH plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell Lymphoma, with Analysis of Germinal Center and Activated B-Cell.

A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of newly diagnosed diffuse large B cell lymphoma Results from a UK NCRI Lymphoma.

SMALL CELL LUNG CANCER 2007 BP HIGGINS MD FRCPC CFPRCC.

Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.

Gray Zone Lymphoma (GZL) with Features Intermediate between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective.

Optimal use of rituximab in aggressive NHL

Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.

CB-1 Background of Pancreatic Cancer & NCIC CTG PA.3 Study Design Malcolm Moore, MD Professor of Medicine and Pharmacology Princess Margaret Hospital Chair,

What is the best approach for a follicular lymphoma patient who achieves CR after frontline chemoimmunotherapy? Radioimmunotherapy! Matthew Matasar,

An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab,

Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.

HL Below the Surface Evaluating Risk of Relapse in Hodgkin Lymphoma.

Relapsed/Refractory Ovarian Cancer: Decision Points in Diagnosis and New Treatment Strategies Friday, March 24, 2006 Palm Springs Convention Center Primrose.

James O. Armitage, M.D. Oncology–Hematology, University of Nebraska Medical Center, Omaha. Address reprint requests to Dr. Armitage at the Division of.

Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma: Final Results of the Phase Ib/II Ro-CHOP Study Dupuis J et al. Proc ASH.

Proton Therapy Patterns-of-Care and Early Outcomes for Hodgkin Lymphoma: Results from the Proton Collaborative Group Registry Bradford Hoppe MD, MPH William.

GALLIUM: Obinutuzumab- vs Rituximab-Based Immunochemotherapy in Patients With Untreated Follicular Lymphoma New Findings in Hematology: Independent Conference.

Abstract ID: #427 Case Report: A Challenging Case of Managing Relapsed & Refractory Hodgkin's Lymphoma Prashanth Hari Dass, Michael B. Jameson, and Elliot.

CCO Independent Conference Highlights

Summary Author: Dr. C. Tom Kouroukis, MD MSc FRCPC

Savage KJ et al. Proc ASH 2015;Abstract 579.

Palumbo A et al. Proc ASH 2012;Abstract 200.

Oki Y et al. Proc ASH 2013;Abstract 252.

CALGB/Alliance 50303: R-CHOP vs DA-EPOCH-R in Newly Diagnosed Diffuse Large B-Cell Lymphoma New Findings in Hematology: Independent Conference Coverage.

Director Department of Pediatric Hematology & Oncology Delhi, INDIA.

New Findings in Hematology: Independent Conference Coverage

Response to chemotherapy

A-I. MD Anderson Cancer Center algorithms for Hodgkin lymphoma

Fenaux P et al. Lancet Oncol 2009;10(3):

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

Jonathan W. Friedberg M.D., M.M.Sc.

Ansell SM et al. Proc ASH 2012;Abstract 798.

Moderate Dose Escalation for Advanced Stage Hodgkin’s Disease Using the Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine,

What is the optimal management of an asymptomatic 62 year old with low tumor burden, stage IV, grade 1-2 FL? Answer: R-chemotherapy Peter Martin,

What is the optimal management of a 43-year-old man with high-risk FL not in CR after R-chemo? Answer: Radioimmunotherapy Peter Martin, M.D. The Charles,

Stephen Ansell, MD, PhD Mayo Clinic

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

Figure 3 Summary of overall survival by Kaplan–Meier

Gordon LI et al. Proc ASH 2010;Abstract 415.

Interim Functional Imaging Is an Independent Predictor of Progression-free Survival in Advanced Classical Hodgkin Lymphoma – A Real-world Analysis Moussab.

The Argument Why This Patient SHOULD Receive “Maintenance” Rituximab

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma1 Phase 3 Randomized Study of Ipilimumab (IPI) plus Dacarbazine (DTIC) vs DTIC.

Volume 19, Issue 10, Pages (October 2018)

Effects of chemotherapy and radiotherapy on spermatogenesis in humans

Hodgkin’s lymphoma stage I/II Untreated, age 15-70

Kaplan-Meier estimates of event-free survival in children with non-Hodgkin lymphoma (n=63). Kaplan-Meier estimates of event-free survival in children with.

by Andrew M. Evens, and Lale Kostakoglu

Bradford Hoppe MD, MPH William Hartsell, MD

Presentation transcript:

E2496 / NCI-C / SWOG / CALG-B: ABVD vs Stanford V in Locally Extensive and Advanced Stage Hodgkin Lymphoma (HL) Gordon LI, et al. ECOG 2496, J Clin Oncol DOI: /JCO Untreated Stage III/IV, or Locally Extensive (>1/3 mediastinum) HL n=854 ABVD x IFRT (36 Gy) to bulky mediastinal lesions n=428 Stratification 0-2 vs 3-7 adverse factors* Locally extensive vs Stage III/IV Stanford V + IFRT (36 Gy) to lesions >5 cm n=426 R ABVDDosage Doxorrubicin25 mg/m 2 IV días 1 y 15 Bleomycin10 u/m 2 IV días 1 y 15 Vinblastine6 mg/m 2 IV días 1 y 15 Dacarbazine375 mg/m 2 IV días 1 y 15 Stanford VDosage Doxorrubicin25 mg/m 2 IV weeks 1, 3, 5, 7, 9 and 11 Vinblastine6 mg/m 2 IV weeks 1, 3, 5, 7, 9 and 11 Nitrogen mustard6 mg/m 2 IV weeks 1, 5, and 9 Etoposide60 mg/m 2 x2 V weeks 3, 7, and 11 Vincristine1.4 mg/m 2 IV weeks 2, 4, 6, 8, 10 and 12 Bleomycin5 u/m 2 IV weeks 2, 4, 6, 8, 10 and 12 Prednisone40 mg q other day x 12 weeks (Taper week 10-12) Creada por: Mauricio Lema Medina MD 1/2 Outcomes Failure-Free Survival (FFS)** Overall Survival (OS) FFS: Time from randomization to progression, relapse or death, whichever occurred first

E2496 / NCI-C / SWOG / CALG-B: ABVD vs Stanford V in Locally Extensive and Advanced Stage Hodgkin Lymphoma (HL) Gordon LI, et al. ECOG 2496, J Clin Oncol DOI: /JCO Creada por: Mauricio Lema Medina MD 2/2 % ABVD remains the standard of care for patients with advanced Hodgkin lymphoma.

Treatment of Advanced Hodgkin Lymphoma: The More Things Change, the More They Stay the Same Longo DL. J Clin Oncol DOI: /JCO